Use of granulocyte colony-stimulating factor (GCSF) for the production of a drug for the treatment of stroke in human patient, comprising administering the GCSF in a total dosage of 80-150 mu g/kg body weight over a treatment period of 2-7 days, is claimed. Independent claims are included for identification of stroke patients by administering GCSF, comprising: determining diffusion weighted image (DWI)-based infarct volume； and identifying the patients with an infarct volume of minimum 16 cm 3>；as a candidate for such treatment, or identifying the patients with an infarct volume with participation of the cortical brain tissue as candidates for purported treatment. ACTIVITY : Cerebroprotective； Vasotropic； Immunostimulant. MECHANISM OF ACTION : None given.
